Wire open Last filed Lilly Pennsylvania plant breaks ground with capacity built for unapproved retatrutide RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire
UrgentTRLNews

PRI 002 phase 2 trial misses Alzheimer efficacy goal but meets safety endpoint

Priavoid says its oral all D peptide did not beat placebo on CDR SB at 48 weeks in 304 patients with early Alzheimer's disease. It points to later per protocol signals, but released no effect sizes or ARIA rates.

Editorial illustration for the story: PRI 002 phase 2 trial misses Alzheimer efficacy goal but meets safety endpoint
Illustration: Peptide Zone. Editorial drawing, not data.

What's new

Priavoid said its oral all D peptide PRI 002 met the primary safety endpoint but missed the primary efficacy endpoint, CDR SB at week 48, in the 304 patient PRImus AD trial.

Why it matters

PRI 002 targets amyloid beta oligomers without antibodies, and the company cites a per protocol ADAS Cog signal at week 72, but no effect sizes or ARIA rates were released.

What's next

Priavoid is analyzing the full dataset, including biomarkers and brain volume, and plans to present it at scientific conferences in 2027 before deciding on a further study.

The PRI 002 phase 2 trial in early Alzheimer's disease missed its main efficacy goal, Priavoid said on 17 November. The oral all D peptide did not beat placebo on the CDR SB dementia rating scale at week 48, though it met the primary safety endpoint. The German company presented the topline data at the Clinical Trials on Alzheimer's Disease conference in Boston. It pointed to numerical trends favoring the drug and a later memory test signal in a subset of patients, and it plans to show the full dataset in 2027.

What PRImus AD tested and who took part

PRImus AD enrolled 304 adults aged 55 to 80 with mild cognitive impairment or mild dementia due to Alzheimer's disease. They were treated at 38 sites in six European countries, which the trial registry lists as Czechia, Germany, Italy, the Netherlands, Poland and Spain. Patients were randomized in equal thirds to one of two daily oral dose levels of PRI 002 or to placebo. The study used a common close design. Everyone was treated for at least 48 weeks, and early enrollees stayed on treatment for up to 96 weeks, until the last patient reached week 48. According to the ClinicalTrials.gov record NCT06182085, dosing began in February 2024 and primary data collection ended in April 2026.

PRI 002 is built from D amino acids, the mirror image forms of the building blocks found in human proteins. Priavoid says the compound binds toxic clumps of amyloid beta, called oligomers, and breaks them back into single harmless units. The company calls this a detangler approach. It contrasts it with the approved anti amyloid antibodies, which clear amyloid through the immune system and carry warnings for ARIA, a form of brain swelling or bleeding seen on scans. Priavoid says its peptide is meant to avoid that immune route. The trial sponsor is PRInnovation GmbH, an affiliate of SPRIND, the German federal agency for breakthrough innovation, which funded the study. Priavoid is a spin off of Heinrich Heine University Düsseldorf and Forschungszentrum Jülich.

Primary endpoint missed while safety goal was met

The trial had two primary endpoints. The safety endpoint covered adverse events, serious adverse events and ARIA, and Priavoid said PRI 002 met it with a favorable safety and tolerability profile. The efficacy endpoint was the change from baseline in CDR SB at week 48, a clinician rating that adds up memory, judgment, community affairs, home life and personal care. That endpoint was not met. The topline release gave no figures for adverse event rates, ARIA cases or the size of any gap between drug and placebo on the rating scale. Without those numbers, outside readers cannot judge how close the trial came or whether the safety profile differs from placebo in a meaningful way. The company said those details will come with the full data.

The topline release gave no figures for adverse event rates, ARIA cases or the size of any gap between drug and placebo on the rating scale.

Priavoid instead pointed to secondary measures. It reported numerical differences favoring PRI 002 on cognition and daily functioning, including the ADAS Cog memory and thinking test and the ADCS ADL daily living scale. These trends grew larger at week 72, the company said, and on ADAS Cog they reached statistical significance in the per protocol population. For the efficacy analysis, the two dose groups were combined because their blood levels of the drug overlapped heavily. Chief medical officer Oliver Peters presented the data. He said a treatment "that could slow cognitive and functional decline while fitting into their daily lives would contribute to quality of life." Chief executive Philipp Bürling called the results "an important milestone" and thanked SPRIND for funding the study.

What the per protocol signal can and cannot show

A per protocol analysis counts only patients who followed the study plan closely. It can show what a drug does under ideal use, but it drops people who stopped early or missed doses, and that can tilt the comparison. The modified intention to treat analysis keeps nearly everyone who was randomized and is usually the stronger test. Under the common close design, only patients who enrolled early reached week 72, so the later signal rests on fewer people than the week 48 result. It also comes from one of several secondary measures. Fierce Biotech summed up the readout as a failure to prove efficacy. The table below sets out what Priavoid has reported so far and what it has not yet released.

ItemWhat Priavoid reported
Participants304 at 38 sites in six European countries
Primary safety endpointMet, no rates given
CDR SB at week 48Not met
ADAS Cog at week 72Significant in the per protocol population only
Dose groupsPooled for efficacy because blood levels overlapped
Full datasetPlanned for scientific conferences in 2027

Alzheimer's drug development has a long record of encouraging subgroup and late time point signals that did not hold in larger trials. A recent example on this site is the semaglutide EVOKE trials, where an approved GLP 1 drug failed to slow early Alzheimer's disease. The PRI 002 case differs because it targets amyloid beta oligomers directly, but the same rule applies. A signal found after a primary miss needs a new trial with that measure as its main endpoint. Chief science officer Dieter Willbold said the preliminary biomarker findings fit the proposed mode of action. The release did not say which plasma or spinal fluid markers changed or by how much, so that claim cannot yet be checked.

Next steps for the detangler program

Priavoid says it is now running a full analysis of the PRI 002 phase 2 data from PRImus AD. This covers more efficacy and safety detail, Alzheimer's markers in blood and spinal fluid, and brain volume scans. The company expects to present the complete dataset at scientific meetings in 2027. Those results will shape next steps, including the possible design of a follow up study, according to the release. Priavoid did not name a partner, a funding plan or a timeline for a Phase 3 trial. Its own description of the program says it is built on a pipeline of detangler compounds aimed at other protein clumping diseases of the brain, but no other candidate has reported human data so far.

Several open questions will decide whether the PRI 002 phase 2 trial supports a larger test. Readers should look for ARIA rates by arm, the actual differences on CDR SB and ADAS Cog with confidence intervals, and how the per protocol and intention to treat groups compare. Brain volume data matter because they give a structural check on any change in test scores. Peer reviewed publication would also allow independent review of the methods. Until then, the topline release is the only public account of the results, and it was written by the company that owns the drug. Further readouts from Alzheimer's and other peptide programs are collected on the Peptide Zone trials desk.

Conclusion

The PRI 002 phase 2 trial met its safety goal but missed its primary efficacy endpoint at week 48. Priavoid points to numerical trends and a per protocol memory test signal at week 72, yet it has released no effect sizes, ARIA rates or biomarker figures. Those details, due in 2027, will show whether the oral peptide has earned a confirmatory trial or remains a hypothesis about amyloid beta oligomers.

More from the wire

Same thread first, then the same desk.